Intellia Therapeutics, Inc.
NASDAQ:NTLABiotechnology
+$0.02 today
- Market cap
- $1.37B
- Beta
- 1.81
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$3.33
Volume 7.23M
Average 6.11M
NTLA Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Intellia Therapeutics, Inc.NASDAQ: NTLA
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation dips below year-ago levels
Q1 FY2026 stock-based compensation of $13.48M fell 38.3% year over year, behind the +2.8% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 85.2% from the prior quarter. Over 3 fiscal years it compounded at +19.1% a year.
Context
- Stock-based compensation amounted to 228.0% of revenue in FY2025, down 38.6 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -38.3% toward the trailing-twelve-month pace of +2.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 154.27M USD
- Year-over-year change
- +0.0%
- 4-year CAGR
- +34.6%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 154.27M | +0.0% |
| FY2024 | 2024-12-31 | 154.27M | +15.1% |
| FY2023 | 2023-12-31 | 134.05M | +46.7% |
| FY2022 | 2022-12-31 | 91.4M | +94.4% |
| FY2021 | 2021-12-31 | 47.01M | — |
Stock-Based Compensation vs competitors
How NTLA compares with its peers on the latest reported figures
- NTLA's LTM Mar 2026 stock-based compensation of $145.91M is the largest of the 10 companies compared; the peer median is $18.36M.
- Its year-over-year change of +2.8% is the 3rd highest of 10, against a peer median of -20.0%.
- Stock-based compensation amounts to 220.8% of revenue for NTLA, versus a peer median of 60.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $145.91M | +2.8% | +19.1% | 220.8% | |
| LTM Sep 2026 | $69.68M | -8.8% | -9.5% | 276.8% | |
| LTM Mar 2026 | $47.93M | +107.3% | -8.3% | 60.1% | |
| LTM Mar 2026 | $35.22M | -20.0% | +6.1% | — | |
| LTM Mar 2026 | $24.1M | -32.3% | -12.7% | — | |
| LTM Mar 2026 | $18.36M | -5.7% | -19.7% | 101.5% | |
| LTM Jun 2026 | $13.14M | +42.2% | +2.1% | 15.3% | |
| LTM Jun 2026 | $12.73M | -111.5% | +3.8% | 8.2% | |
| LTM Mar 2026 | $11.16M | -32.8% | +2.7% | 99.6% | |
| LTM Mar 2026 | $9.12M | -45.7% | -30.1% | 23.6% | |
| Peer median (excluding NTLA) | $18.36M | -20.0% | -8.3% | 60.1% | |
Competitors are the stored peer set for NTLA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (267.89M) | (474.19M) | (481.19M) | (519.02M) | (519.02M) |
| Depreciation & Amortization | 6.89M | 7.57M | 8.98M | 10.29M | 10.29M |
| Deferred Income Tax | 8.93M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 47.01M | 91.4M | 134.05M | 154.27M | 154.27M |
| Change in Working Capital | (22.9M) | (53.87M) | (52.45M) | 11.88M | (73.75M) |
| Accounts Receivables | 99K | (1.74M) | (32.69M) | 27.94M | (951K) |
| Inventory | 7.82M | 0 | 0 | 0 | 0 |
| Accounts Payables | 529K | (4.58M) | 2.52M | 6.8M | 5.99M |
| Other Working Capital | (31.36M) | (47.55M) | (22.29M) | (22.86M) | (78.79M) |
| Other Non-Cash Items | 2.94M | 95.8M | (3.47M) | (6.3M) | 79.34M |
| Operating Cash Flow | (225.03M) | (333.29M) | (394.09M) | (348.88M) | (348.88M) |
| Capital Expenditures | (12.76M) | (58.39M) | (13.99M) | (5.78M) | (5.78M) |
| Acquisitions (Net) | (3M) | (44.68M) | 0 | 0 | 0 |
| Purchases of Investments | (1.02B) | (429.03M) | (904.46M) | (935.57M) | (935.57M) |
| Sales of Investments | 485.6M | 647.58M | 887.1M | 1.07B | 1.05B |
| Other Investing Activities | 0 | 44.83M | 0 | 0 | 20.97M |
| Investing Cash Flow | (550.78M) | 160.31M | (31.35M) | 125.57M | 125.57M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 693.57M | 565.79M | 119.8M | 176.9M | 131.49M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 43.12M | 17.17M | 10.53M | 8.85M | 54.26M |
| Financing Cash Flow | 736.69M | 582.96M | 130.32M | 185.75M | 185.75M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (39.12M) | 409.98M | (295.11M) | (37.57M) | (37.57M) |
| Free Cash Flow | (237.79M) | (391.68M) | (408.07M) | (354.66M) | (354.66M) |
Intellia Therapeutics, Inc.
NASDAQ:NTLA
Intrinsic Alpha fair value
Locked
Current Price
$9.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.